Dura Pharmaceuticals, Inc. v. Broudo

Background

A group of individual investors bought shares of a drug company between April 15, 1997, and February 24, 1998. They sued the company and some managers, saying the company lied about drug profits and that the Food and Drug Administration would approve a new spray device. On February 24 the company announced lower earnings and the stock fell from about $39 to $21 the next day. Months later the FDA denied approval and the price briefly fell but then nearly recovered. The investors’ complaint mainly said they paid “artificially inflated” prices and were damaged.

Reasoning

The Court addressed whether simply alleging that the purchase price was inflated proves that the misstatement caused an economic loss. The Court explained that paying too much at purchase does not always cause an actual loss because ownership of the stock offsets the payment at that moment. Later price drops can reflect many other business or market events, not the earlier lie. Pointing to common-law fraud principles and the securities law, the Court held plaintiffs must plead and later prove that the defendant’s misrepresentation proximately caused the plaintiff’s actual economic loss. The Ninth Circuit’s rule that price inflation at purchase alone sufficed was rejected, and the Court found the investors’ complaint legally insufficient.

Real world impact

The ruling requires investors bringing private securities suits to identify and prove the specific economic loss tied to the alleged lie. It gives companies clearer notice of the loss claims they must defend and makes it harder to rely solely on an inflated purchase price. The case was reversed and sent back to the lower court for further proceedings consistent with this opinion.